Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
Novocure, a global oncology company, is set to present new data on Tumor Treating Fields (TTFields) therapy at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid. The company will showcase three posters, including an analysis of patient-reported health-related quality of life scores from the phase 3 LUNAR clinical trial in metastatic non-small cell lung cancer (NSCLC).
One of the key findings from the analysis is that the addition of TTFields therapy to standard systemic therapies did not negatively impact patients’ quality of life. The study utilized The European Organization for Research and Treatment of Cancer Quality of Life questionnaire-C30 and showed no statistically significant difference in median time to deterioration for global health status and various functional scales between patients who received TTFields therapy and those who received standard systemic therapies alone.
Novocure will also present global post-marketing surveillance data from patients with high-grade gliomas, confirming the well-tolerated safety profile of TTFields therapy in older patients. This data aligns with findings from Novocure’s EF-14 clinical trial. Additionally, survey data from patients with glioblastoma (GBM) in the United States and the DACH region (Germany, Austria, and Switzerland) revealed high levels of satisfaction with TTFields therapy, with most patients stating they would recommend it to others with GBM.
To further highlight the significance of TTFields therapy, Novocure will host an industry-sponsored symposium titled “The Evolving Role of TTFields Therapy in Solid Tumors” during the ESMO Congress.
Pritesh Shah, Novocure’s Chief Growth Officer, expressed enthusiasm about the new data, stating that it supports the use of TTFields therapy in managing metastatic NSCLC and reinforces the therapy’s favorable safety profile and patient satisfaction. Novocure looks forward to sharing these insights with leading medical oncologists and continuing to learn from them.
Novocure’s Tumor Treating Fields therapy utilizes electric fields to target and kill cancer cells through various mechanisms. The therapy selectively targets cancer cells while sparing healthy cells, making it a versatile option that can be combined with other cancer treatments. Novocure’s ongoing and completed clinical trials are investigating the efficacy of TTFields therapy in various solid tumors, including brain metastases, gastric cancer, liver cancer, and ovarian cancer.
Novocure, headquartered in Switzerland, is dedicated to extending survival in aggressive forms of cancer through the development and commercialization of innovative therapies like TTFields. The company’s products have gained approval in certain countries for the treatment of glioblastoma, malignant pleural mesothelioma, and pleural mesothelioma.
With a growing global footprint, Novocure has regional operating centers in New Hampshire and Tokyo, as well as a research center in Israel. The company continues to drive scientific progress, clinical trial advancements, and the development of potential products to improve outcomes for cancer patients.
Novocure’s participation in the ESMO Congress 2023 and the presentation of these new data underscore the company’s commitment to advancing cancer treatment and improving patients’ lives.